Contract manufacturers, laboratories, and packagers are responsible for selecting and monitoring qualified firms and, in some cases, their suppliers. These entities are subject to FDA inspections, and violations, including noncompliance with current Good Manufacturing Practices (cGMP), can result in enforcement actions that may disrupt operations or product distribution. Manufacturers within the prescription drug supply chain must adhere to product tracking, tracing, and reporting requirements to address counterfeit or adulterated products. Compliance with cGMP and regulatory standards necessitates ongoing investment in production and quality control. The FDA may withdraw product approval or impose restrictions and penalties if compliance issues or safety concerns arise, including product recalls, fines, refusal of application approvals, product seizures, consent decrees, and civil or criminal penalties. Marketing and promotion of biological products are regulated to permit only FDA-approved claims, with enforcement actions against off-label promotion. Physicians may legally prescribe products for off-label uses.
Absci's Comment on Supply Chain
Contract manufacturers, laboratories, and packagers are responsible for selecting and monitoring qualified firms and, in some cases, their suppliers. These entities are subject to FDA inspections, and violations, including noncompliance with current Good Manufacturing Practices (cGMP), can result in enforcement actions that may disrupt operations or product distribution. Manufacturers within the prescription drug supply chain must adhere to product tracking, tracing, and reporting requirements to address counterfeit or adulterated products. Compliance with cGMP and regulatory standards necessitates ongoing investment in production and quality control. The FDA may withdraw product approval or impose restrictions and penalties if compliance issues or safety concerns arise, including product recalls, fines, refusal of application approvals, product seizures, consent decrees, and civil or criminal penalties. Marketing and promotion of biological products are regulated to permit only FDA-approved claims, with enforcement actions against off-label promotion. Physicians may legally prescribe products for off-label uses.
Sources:
Absci Corp's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Absci Corp’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
